State Specialty Directory
Ophthalmology in TX
Federal CMS data for 1408 ophthalmology providers across TX. Includes Medicare utilization, Open Payments industry funding, and PECOS enrollment status.
1408
Providers
Median industry payments
$1,287
1408
Ophthalmology Providers
in TX
$1,287
Median Industry Payments
per provider (2018–2024)
678
Median Medicare Services
fee-for-service claims
How to read this directory: Providers are listed by Medicare service volume, which reflects only
Medicare fee-for-service patients (typically 65+). This does not represent total practice volume.
Industry payments span multiple years and payment types — they are legal and do not indicate wrongdoing.
Ophthalmology includes multiple subspecialties with different practice patterns.
Learn more →
Showing top 50 of 1408 providers, ranked by Medicare service volume. Search by city to narrow results.
Ophthalmology Providers — TX
NPPES · Open Payments · Medicare| Provider | City | Medicare Volume | Beneficiaries* | Top Procedure | Industry Payments | Payment Type | Coverage |
|---|---|---|---|---|---|---|---|
| RUSH, RYAN MD | AMARILLO | 222,813 | 8,909 | Eye injection (Vabysmo/faricimab) | $3,958 (2018-2022) | Ownership/Investment (93%) | Very High |
| YSASAGA, JASON M.D. | AMARILLO | 202,989 | 13,332 | Eye injection (Vabysmo/faricimab) | $13,960 (2018-2024) | Consulting (39%) | Very High |
| QURESHI, JAWAD MD | SOUTHLAKE | 189,779 | 6,672 | Eye injection (Vabysmo/faricimab) | $3,569 (2018-2024) | Food & Beverage (47%) | Very High |
| ARAGON, ANTONIO M.D. | AMARILLO | 158,547 | 9,653 | Eye injection (Vabysmo/faricimab) | $4,610 (2018-2024) | Ownership/Investment (80%) | Very High |
| ABBEY, ASHKAN M.D. | DALLAS | 129,195 | 6,075 | Eye injection (Vabysmo/faricimab) | $507,093 (2018-2024) | Consulting (64%) | Very High |
| WANG, ROBERT M.D. | DALLAS | 74,847 | 4,350 | Eye injection (Vabysmo/faricimab) | $159,094 (2018-2024) | Consulting (72%) | Very High |
| OEI, THOMAS MD | SAN ANTONIO | 69,047 | 9,024 | Eye injection (Vabysmo/faricimab) | $7,417 (2018-2024) | Food & Beverage (99%) | Very High |
| FULLER, CHRISTOPHER M.D. | LUBBOCK | 63,918 | 4,415 | Eye injection (Vabysmo/faricimab) | $61,731 (2018-2024) | Consulting (41%) | Very High |
| COORS, LORI M.D. | DALLAS | 61,127 | 6,219 | Eye injection (Vabysmo/faricimab) | $6,110 (2018-2024) | Consulting (57%) | Very High |
| MCCLELLAN, ANDREW MD | DALLAS | 58,987 | 4,723 | Eye injection (Vabysmo/faricimab) | $5,564 (2018-2024) | Gift (26%) | Very High |
| FULLER, TIMOTHY MD | DALLAS | 45,294 | 5,129 | Eye injection (Vabysmo/faricimab) | $1,167 (2018-2024) | Food & Beverage (100%) | Very High |
| LAM, MICHAEL M.D. | HOUSTON | 41,727 | 2,738 | Eye injection (Vabysmo/faricimab) | $3,764 (2018-2024) | Food & Beverage (91%) | Very High |
| LANE, RICHARD M.D. | SAN ANTONIO | 41,700 | 4,208 | Eye injection (Vabysmo/faricimab) | $16,675 (2018-2024) | Acquisitions (51%) | Very High |
| KHAWLY, JOSEPH MD | HOUSTON | 39,099 | 6,841 | Eye injection (Vabysmo/faricimab) | $45,966 (2018-2024) | Ownership/Investment (76%) | Very High |
| KOZIELEC, GREGORY MD | DALLAS | 34,911 | 7,457 | Injection, ranibizumab, 0.1 mg | $4,471 (2018-2024) | Consulting (79%) | Very High |
| WILLIAMS, PATRICK M.D. | ARLINGTON | 34,559 | 3,233 | Eye injection (Vabysmo/faricimab) | $20,353 (2018-2024) | Consulting (81%) | Very High |
| WONG, ROBERT MD | AUSTIN | 32,276 | 3,955 | Eye injection (Vabysmo/faricimab) | $112,670 (2018-2024) | Consulting (90%) | Very High |
| CASTILLO-SALAZAR, IVAN MD | WACO | 32,161 | 4,739 | Eye injection (Vabysmo/faricimab) | $7,676 (2018-2024) | Food & Beverage (98%) | Very High |
| TZU, JONATHAN MD | HOUSTON | 31,553 | 3,424 | Eye injection (Vabysmo/faricimab) | $22,988 (2018-2024) | Consulting (66%) | Very High |
| TRAN, LEE MD | HOUSTON | 31,007 | 2,259 | Eye injection (Vabysmo/faricimab) | $3,856 (2018-2024) | Food & Beverage (99%) | Very High |
| CHONG, DEBORAH MD | DALLAS | 29,548 | 2,722 | Eye injection (Vabysmo/faricimab) | $8,231 (2018-2024) | Consulting (61%) | Very High |
| PATEL, AMAR MD | TYLER | 29,298 | 6,056 | Injection, ranibizumab, 0.1 mg | $1,377 (2018-2024) | Food & Beverage (100%) | Very High |
| BROWN, JEREMIAH MD | SCHERTZ | 28,417 | 4,311 | Eye injection (Vabysmo/faricimab) | $289,444 (2018-2024) | Consulting (67%) | Very High |
| GALLAGHER, JENNIFER M.D. | AMARILLO | 28,393 | 2,816 | Eye injection (Vabysmo/faricimab) | $3,263 (2019-2024) | Food & Beverage (63%) | Very High |
| SHAMI, MICHEL M.D. | LUBBOCK | 28,039 | 3,639 | Eye injection (Vabysmo/faricimab) | $1,319 (2018-2024) | Food & Beverage (99%) | Very High |
| PATEL, SUNIL MD, PHD | ABILENE | 27,954 | 5,390 | Eye injection (Vabysmo/faricimab) | $55,431 (2018-2024) | Consulting (61%) | Very High |
| SAULNY, STANLEY M.D. | W LAKE HILLS | 27,923 | 1,703 | Botox injection, per unit | $2,021 (2018-2024) | Food & Beverage (100%) | Very High |
| SINGER, MICHAEL M.D. | SAN ANTONIO | 27,145 | 3,042 | Eye injection (Vabysmo/faricimab) | $1,715,514 (2018-2024) | Consulting (74%) | Very High |
| KOTHARI, NIKISHA M.D. | ARLINGTON | 26,547 | 2,522 | Eye injection (Vabysmo/faricimab) | $13,932 (2018-2024) | Consulting (77%) | Very High |
| LEUNG, ELLA M.D. | HOUSTON | 26,286 | 2,258 | Eye injection (Vabysmo/faricimab) | $10,893 (2018-2024) | Food & Beverage (82%) | Very High |
| SYRQUIN, MAURICE MD | DALLAS | 26,246 | 6,584 | Injection, ranibizumab, 0.1 mg | $128 (2019-2024) | Food & Beverage (100%) | Very High |
| JHAVERI, CHIRAG M.D. | AUSTIN | 25,353 | 2,483 | Eye injection (Vabysmo/faricimab) | $192,551 (2018-2024) | Consulting (81%) | Very High |
| SOLLEY, WAYNE M.D. | ARLINGTON | 24,370 | 3,770 | Eye injection (Vabysmo/faricimab) | $23,772 (2018-2024) | Consulting (76%) | Very High |
| RAHMAN, HASSAN M.D. | HOUSTON | 24,366 | 3,585 | Eye injection (Vabysmo/faricimab) | $4,437 (2018-2024) | Food & Beverage (51%) | Very High |
| WITHERSPOON, SCOTT MD | DALLAS | 23,412 | 3,949 | Injection, ranibizumab, 0.1 mg | $305 (2018-2024) | Food & Beverage (100%) | Very High |
| BOCHOW, THOMAS M.D., M.P.H. | TYLER | 23,400 | 4,257 | Eye injection (Vabysmo/faricimab) | $1,486 (2018-2024) | Travel (56%) | Very High |
| STEWART, PAUL MD | BELLAIRE | 23,363 | 2,486 | Eye injection (Vabysmo/faricimab) | $3,506 (2018-2024) | Food & Beverage (99%) | Very High |
| HARRIS, LINDSEY MD | HOUSTON | 23,138 | 3,889 | Eye injection (Vabysmo/faricimab) | $8,996 (2018-2024) | Food & Beverage (52%) | Very High |
| LAURA, DIANA MD | DALLAS | 22,861 | 2,707 | Eye injection (Vabysmo/faricimab) | $4,913 (2018-2024) | Food & Beverage (100%) | Very High |
| BENZ, MATTHEW MD | HOUSTON | 22,777 | 3,921 | Aflibercept eye injection (Eylea) | $14,965 (2018-2024) | Consulting (83%) | Very High |
| NIXON, PETER MD | AUSTIN | 22,502 | 6,038 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | $4,066 (2018-2024) | Food & Beverage (45%) | Very High |
| DATE, RISHABH M.D. | BELLAIRE | 22,139 | 4,460 | Eye injection (Vabysmo/faricimab) | $3,259 (2018-2024) | Food & Beverage (89%) | Very High |
| ALAPPATT, JOHN M.D. | HOUSTON | 20,640 | 1,879 | Eye injection (Vabysmo/faricimab) | $4,240 (2018-2024) | Food & Beverage (88%) | Very High |
| CLARK, CHARLES M.D. | ABILENE | 20,558 | 3,276 | Eye injection (Vabysmo/faricimab) | $6,169 (2018-2024) | Consulting (69%) | Very High |
| MARTINEZ, JOSE MD | AUSTIN | 20,534 | 3,665 | Eye injection (Vabysmo/faricimab) | $40,167 (2018-2024) | Consulting (88%) | Very High |
| ALLEN, MARCUS MD | DALLAS | 20,107 | 4,385 | Injection, ranibizumab, 0.1 mg | $323 (2018-2024) | Food & Beverage (100%) | Very High |
| ALSHEIKH, ODAY M.D. | SAN ANTONIO | 19,602 | 9,695 | Microfluid analysis of tears | $8,805 (2018-2024) | Food & Beverage (64%) | Very High |
| FISH, GARY M.D. | DALLAS | 19,196 | 3,594 | Eye injection (Vabysmo/faricimab) | $56 (2022-2024) | Food & Beverage (74%) | Very High |
| BASKIN, DARRELL MD | SAN ANTONIO | 19,185 | 2,195 | Eye injection (Vabysmo/faricimab) | $13,923 (2018-2024) | Acquisitions (61%) | Very High |
| CHOI, HENRY MD | DESOTO | 18,726 | 2,098 | Eye injection (Vabysmo/faricimab) | $5,652 (2018-2024) | Food & Beverage (93%) | Very High |
Note: Ophthalmology encompasses multiple subspecialties with different practice patterns.
Differences in payment amounts and procedure volumes may reflect subspecialty focus
rather than practice quality. Consider viewing individual profiles for full context.